Lexicon Pharmaceuticals Inc. (LXRX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Lexicon Pharmaceuticals Inc. (LXRX) slipped -0.34% to $1.48, trading at 24% of its 52-week range ($1.1 – $2.68). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 f
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial o
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing pivotal Phase 3
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet ac
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of sotagliflozin on platelet
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LXRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LXRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexicon Pharmaceuticals Inc. (LXRX) ranks #666 by composite RQD confidence (39/100, grade D-) and #408 by equity capitalization ($658.5M). Within this direct 5-issuer industry benchmark cohort, LXRX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with LXRX at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LXRX
ACTIVE
Lexicon Pharmaceuticals Inc. | D- | 39/100 | — | 96.0% | -31.5% | -0.34% | $658.5M | Benchmark Subject |
| ABUS Arbutus Biopharma Corporation | E | 22/100 | — | — | -35.0% | -0.93% | $656.0M | /abus-vs-lxrx → |
| IMMX Immix Biopharma Inc. | E | 33/100 | — | — | -35.0% | -1.78% | $661.6M | /immx-vs-lxrx → |
| ANL Adlai Nortye Group Ltd. | D+ | 52/100 | — | — | — | +0.78% | $662.0M | /anl-vs-lxrx → |
| BCAX Bicara Therapeutics Inc. | D | 45/100 | — | — | -35.0% | -0.31% | $643.9M | /bcax-vs-lxrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported GAAP revenue of $49.8M (+729.9% vs. FY2024 revenue of $6.0M , and +4386.8% cumulative change since FY2023) , GAAP net income of -$50.3M, operating cash flow of -$67.9M, and free cash flow of -$67.9M (+62.3% YoY). On the balance sheet, LXRX closed FY2025 with $185.0M in total assets against $49.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $49.8M | -$50.3M | -$67.9M | -$67.9M | $185.0M | $49.4M |
| FY2024 (FY) | 2024-12-31 | $6.0M | -$200.4M | -$178.8M | -$179.8M | $298.4M | $100.3M |
| FY2023 (FY) | 2023-12-31 | $1.1M | -$177.1M | -$161.9M | -$161.9M | — | — |
As of 2026-11-01, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.48 (-0.34% 1D, market cap $658.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LXRX ranks #666 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, ABUS (Arbutus Biopharma Corporation) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M) and IMMX (Immix Biopharma Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
LXRX last traded at $1.48 (-0.34% on volume of 1,772,659 shares), positioning the stock -21.69% below its 50-day simple moving average ($1.89) and -21.28% below its 200-day simple moving average ($1.88). Across its 52-week range of $1.10 to $2.68, LXRX sits at the 24.1% percentile with a 14-day RSI of 29.1 (OVERSOLD (<32)) and an implied next-earnings move of ±11.6% ($1.31 to $1.65).
Why LXRX Stock slipped -0.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.